Efectividad cognitiva del metilfenidato y de la atomoxetina en el trastorno por déficit de atención con hiperactividad: una revisión

Descargas

Publicado

2016-09-30

Cómo citar

Rubio, B., Hernández, S., Herreros, O., Gastaminza, X., Cejas, R., & Castrillo, J. (2016). Efectividad cognitiva del metilfenidato y de la atomoxetina en el trastorno por déficit de atención con hiperactividad: una revisión. Revista De Psiquiatría Infanto-Juvenil, 33(3), 367–377. https://doi.org/10.31766/revpsij.v33n3a1

Número

Sección

Artículo de revisión

Autores/as

  • Belén Rubio Hospital Universitario de Canarias
  • Sergio Hernández Universidad de La Laguna
  • Oscar Herreros Hospital Universitario Virgen de las Nieves
  • Xavier Gastaminza Universitat Autonoma de Barcelona
  • Rosario Cejas Hospital Universitario de Canarias
  • Jennifer Castrillo Universidad de La Laguna

DOI:

https://doi.org/10.31766/revpsij.v33n3a1

Palabras clave:

Atomoxetina, Evaluación Neuropsicológica, Metilfenidato, Neuropsicología Infantil, Niños, Psiquiatría Infantil

Resumen

Introducción. El Trastorno por Déficit de Atención con Hiperactividad (TDAH) se asocia a importantes déficits en diversos dominios cognitivos. Dicha afirmación cuenta con evidencias cognitivo-conductuales y neurofuncionales. El tratamiento farmacológico indicado en esta población tiene como objetivo fundamental suprimir o reducir la sintomatología nuclear del trastorno. Esta es la diana terapéutica tanto del Metilfenidato como de la Atomoxetina. Ambos actúan sobre la corteza prefrontal y sus conexiones con los ganglios basales, parte del sustrato anatómico de la atención, la actividad motora y el control inhibitorio. Considerando que estas regiones forman parte del conjunto de áreas y circuitos implicados en el procesamiento cognitivo complejo, se puede colegir que los acercamientos farmacológicos eficaces en la mejora de la sintomatología nuclear de este trastorno tendrán un efecto beneficioso sobre la ejecución cognitiva de estos pacientes, y, por extensión, sobre el rendimiento académico.

Objetivo. Actualizar los conocimientos existentes en neurociencia sobre la repercusión cognitiva de la administración de Metilfenidato y Atomoxetina en población con TDAH. Es un interés central del estudio profundizar en la relación entre sintomatología nuclear, sustrato anatomopatológico y rendimiento cognitivo, con especial referencia a las funciones ejecutivas. 

Método. Se ha realizado una exhaustiva revisión bibliográfica en la bases Pubmed, PsycINFO y Medline con las palabras clave: Metilfenidato, Atomoxetina, TDAH, Tratamiento, Evaluación neuropsicológica y Neuropsicología infantil. 

Conclusiones. El metilfenidato ha mostrado superioridad a la atomoxetina en el control de la sintomatología nuclear. Sin embargo, sobre el funcionamiento cognitivo, y en especial sobre la memoria de trabajo, ambos fármacos muestran efectos beneficiosos comparables.

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

Belén Rubio, Hospital Universitario de Canarias

Facultativo especialista en Psiquiatría. 

Correspondencia:
Belén Rubio Morell.
Unidad de Psiquiatría Infanto-Juvenil, Hospital Universitario de Canarias, La Laguna, Tenerife.
rubiobelen@gmail.com.

Sergio Hernández, Universidad de La Laguna

Profesor Titular de Neuropsicología. Dpto. Psicología Clínica, Psicobiología y Metodología. Facultad de Ciencias de la Salud, Sección de Psicología y Logopedia, Universidad de La Laguna.

Oscar Herreros, Hospital Universitario Virgen de las Nieves

Psiquiatra Facultativo especialista de Área. Unidad de Salud Mental Infanto-Juvenil. Hospital Universitario Virgen de las Nieves, Granada.

Xavier Gastaminza, Universitat Autonoma de Barcelona

Facultativo especialista en Psiquiatría. NOVOMEDIGRUP. Paidopsiquiatría psicosomática. Unidad de Paidopsiquiatría. Hospital Universitari Vall d’Hebron, Barcelona. Universitat Autonoma de Barcelona.

Rosario Cejas, Hospital Universitario de Canarias

Facultativo especialista en Psiquiatría. Hospital Universitario de Canarias, La Laguna.

Jennifer Castrillo, Universidad de La Laguna

Psicóloga. Dpto. Psicología Clínica, Psicobiología y Metodología. Facultad de Ciencias de la Salud, Sección de Psicología, Universidad de La Laguna.

Citas

Catalá-López F, Peiró S, Ridao M, Sanfélix-Gimeno G, Gènova-Maleras R, Catalá MA. Prevalence of attention deficit hyperactivity disorder among children and adolescents in Spain: a systematic review and meta-analysis of epidemiological studies. BMC Psychiatry. 2012;12(1):168. DOI: https://doi.org/10.1186/1471-244X-12-168

Willcutt EG. The prevalence of DSM-IV attentiondeficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics. 2012;9(3):490–9. DOI: https://doi.org/10.1007/s13311-012-0135-8

Solanto MV, Abikoff H, Sonuga-Barke E, Schachar R, Logan GD, Wigal T, et al. The ecological validity of delay aversion and response inhibition as measures of impulsivity in AD/HD: a supplement to the NIMH multimodal treatment study of AD/HD. J Abnorm Child Psychol. 2001;29(3):215–28. DOI: https://doi.org/10.1023/A:1010329714819

Escobar R. Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics. 2005;116(3):e364–9. DOI: https://doi.org/10.1542/peds.2005-0386

Brown TE, Reichel PC, Quinlan DM. Executive function impairments in high IQ adults with ADHD. J Atten Disord. 2009;13(2):161–7. DOI: https://doi.org/10.1177/1087054708326113

Maziade M, Rouleau N, Lee B, Rogers A, Davis L, Dickson R. Atomoxetine and neuropsychological function in children with attention-deficit/hyperactivity disorder: results of a pilot study. J Child Adolesc Psychopharmacol. 2009;19(6):709–18. DOI: https://doi.org/10.1089/cap.2008.0166

Pliszka SR. The neuropsychopharmacology of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57(11):1385–90. DOI: https://doi.org/10.1016/j.biopsych.2004.08.026

Biederman J. Attention-deficit/hyperactivity disorder: A selective overview. Biol Psychiatry. 2005;57(11):1215–20. DOI: https://doi.org/10.1016/j.biopsych.2004.10.020

Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet; 366(9481):237–48. DOI: https://doi.org/10.1016/S0140-6736(05)66915-2

Swanson JM, Wigal SB, Udrea D, Lerner M, Agler D, Flynn D, et al. Evaluation of individual subjects in the analog classroom setting: I. Examples of graphical and statistical procedures for withinsubject ranking of responses to different delivery patterns of methylphenidate. Psychopharmacol Bull. 1998;34(4):825–32.

Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, et al. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108(4):883–92. DOI: https://doi.org/10.1542/peds.108.4.883

Swanson J, Baler RD, Volkow ND. Understanding the effects of stimulant medications on cognition in individuals with attention-deficit hyperactivity disorder: a decade of progress. Neuropsychopharmacology. 2011;36(1):207–26. DOI: https://doi.org/10.1038/npp.2010.160

Starr HL, Kemner J. Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD. J Natl Med Assoc. 2005;97(10 Suppl):11S–16S.

Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry. 2008;165(6):721–30. DOI: https://doi.org/10.1176/appi.ajp.2007.05091676

DuPaul GJ, Barkley RA, McMurray MB. Response of children with ADHD to methylphenidate: interaction with internalizing symptoms. J Am Acad Child Adolesc Psychiatry. ;33(6):894–903 DOI: https://doi.org/10.1097/00004583-199407000-00016

Psychopathology C, Edition S, Mash EJ, Barkley RA, Barkley RA. Attention-Deficit/ Hyperactivity Disorder. 2003

Castellanos FX, Tannock R. Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes. Nat Rev Neurosci. 2002;3(8):617–28. DOI: https://doi.org/10.1038/nrn896

Oades RD, Sadile AG, Sagvolden T, Viggiano D, Zuddas A, Devoto P, et al. The control of responsiveness in ADHD by catecholamines: Evidence for dopaminergic, noradrenergic and interactive roles. Dev Sci. 2005;8(2):122–31. DOI: https://doi.org/10.1111/j.1467-7687.2005.00399.x

Sonuga-Barke EJS. Causal models of attentiondeficit/hyperactivity disorder: from common simple deficits to multiple developmental pathways. Biol Psychiatry. 2005;57(11):1231–8. DOI: https://doi.org/10.1016/j.biopsych.2004.09.008

Wilens TE, Biederman J. The stimulants. Psychiatr Clin North Am. 1992;15(1):191–222. DOI: https://doi.org/10.1016/S0193-953X(18)30265-X

Sonuga-Barke EJS, Coghill D, Wigal T, DeBacker M, Swanson J. Adverse reactions to methylphenidate treatment for attention-deficit/hyperactivity disorder: structure and associations with clinical characteristics and symptom control. J Child Adolesc Psychopharmacol. 2009;19(6):683–90. DOI: https://doi.org/10.1089/cap.2009.0024

Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics. 1990;86(2):184–92. DOI: https://doi.org/10.1542/peds.86.2.184

Pietrzak RH, Mollica CM, Maruff P, Snyder PJ. Cognitive effects of immediate-release methylphenidate in children with attention-deficit / hyperactivity disorder. 2006;30:1225–45.

Aron AR, Dowson JH, Sahakian BJ, Robbins TW. Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2003;54(12):1465–8. DOI: https://doi.org/10.1016/S0006-3223(03)00609-7

Aron AR, Robbins TW, Poldrack RA. Inhibition and the right inferior frontal cortex: one decade on. Trends Cogn Sci. 2014;18(4):177–85. DOI: https://doi.org/10.1016/j.tics.2013.12.003

Rhodes SM, Coghill DR, Matthews K. Neuropsychological functioning in stimulantnaive boys with hyperkinetic disorder. Psychol Med. 2005;35(8):1109–20. DOI: https://doi.org/10.1017/S0033291705004599

Rhodes SM, Coghill DR, Matthews K. Methylphenidate restores visual memory, but not working memory function in attention deficithyperkinetic disorder. Psychopharmacology (Berl). 2004;175(3):319–30. DOI: https://doi.org/10.1007/s00213-004-1833-7

Vance A, Ferrin M, Winther J, Gomez R. Examination of spatial working memory performance in children and adolescents with attention deficit hyperactivity disorder, combined type (ADHD-CT) and anxiety. J Abnorm Child Psychol. 2013;41(6):891–900. DOI: https://doi.org/10.1007/s10802-013-9721-4

Smith AB, Taylor E, Brammer M, Halari R, Rubia K. Reduced activation in right lateral prefrontal cortex and anterior cingulate gyrus in medication-naïve adolescents with attention deficit hyperactivity disorder during time discrimination. J Child Psychol Psychiatry. 2008;49(9):977–85. DOI: https://doi.org/10.1111/j.1469-7610.2008.01870.x

Smith A, Cubillo A, Barrett N, Giampietro V, Simmons A, Brammer M, et al. Neurofunctional effects of methylphenidate and atomoxetine in boys with attention-deficit/hyperactivity disorder during time discrimination. Biol Psychiatry. 2013;74(8):615–22. DOI: https://doi.org/10.1016/j.biopsych.2013.03.030

Vaidya CJ, Austin G, Kirkorian G, Ridlehuber HW, Desmond JE, Glover GH, et al. Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study. Proc Natl Acad Sci. 1998;95(24):14494–9. DOI: https://doi.org/10.1073/pnas.95.24.14494

Pauls AM, Daly OG, Rubia K, Riedel WJ, Williams SCR, Mehta MA. Methylphenidate effects on prefrontal functioning during attentionalcapture and response inhibition. Biol Psychiatry. 2012;72(2):142–9. DOI: https://doi.org/10.1016/j.biopsych.2012.03.028

Mehta MA, Goodyer IM, Sahakian BJ. Methylphenidate improves working memory and set-shifting in AD/HD: relationships to baseline memory capacity. J Child Psychol Psychiatry. 2004;45(2):293–305. DOI: https://doi.org/10.1111/j.1469-7610.2004.00221.x

Mehta MA, Owen AM, Sahakian BJ, Mavaddat N, Pickard JD, Robbins TW. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neurosci. 2000;20(6):RC65. DOI: https://doi.org/10.1523/JNEUROSCI.20-06-j0004.2000

Devilbiss DM, Berridge CW. Low-dose methylphenidate actions on tonic and phasic locus coeruleus discharge. J Pharmacol Exp Ther. 2006;319(3):1327–35. DOI: https://doi.org/10.1124/jpet.106.110015

Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AFT, Kelley AE, Schmeichel B, et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry. 2006;60(10):1111–20. DOI: https://doi.org/10.1016/j.biopsych.2006.04.022

Pietrzak R, Mollica C, Maruff P, Snyder P. Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. Neurosci Biobehav Rev. 2006;30(8):1225–45. DOI: https://doi.org/10.1016/j.neubiorev.2006.10.002

Rapport MD, Carlson GA, Kelly KL, Pataki C. Methylphenidate and desipramine in hospitalized children: I. separate and combined effects on cognitive function. J Am Acad Child Adolesc Psychiatry. 1993;32(2):333–42. DOI: https://doi.org/10.1097/00004583-199303000-00014

Coghill D, Banaschewski T, Zuddas A, Pelaz A, Gagliano A, Doepfner M. Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies. BMC Psychiatry. 2013;13(1):237. DOI: https://doi.org/10.1186/1471-244X-13-237

Rapport MD, Kelly KL. Psychostimulant effects on learning and cognitive function. In: Handbook of hyperactivity in children. 1993. p. 97–136.

Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27(5):699–711. DOI: https://doi.org/10.1016/S0893-133X(02)00346-9

Stahl SM. Neurotransmission of cognition, part 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition. J Clin Psychiatry. 2003;64(2):110–1. DOI: https://doi.org/10.4088/JCP.v64n0201

Simpson D, Perry CM. Atomoxetine. Paediatr Drugs. 2003;5(6):407–15 DOI: https://doi.org/10.2165/00128072-200305060-00005

Ding YS, Naganawa M, Gallezot JD, Nabulsi N, Lin SF, Ropchan J, et al. Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD. Neuroimage. 2014;86:164–71. DOI: https://doi.org/10.1016/j.neuroimage.2013.08.001

Gallezot JD, Weinzimmer D, Nabulsi N, Lin SF, Fowles K, Sandiego C, et al. Evaluation of [(11)C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates. Neuroimage. 2011;56(1):268–79. DOI: https://doi.org/10.1016/j.neuroimage.2010.09.040

Wee S, Woolverton WL. Evaluation of the reinforcing effects of atomoxetine in monkeys: comparison to methylphenidate and desipramine. Drug Alcohol Depend. 2004;75(3):271–6. DOI: https://doi.org/10.1016/j.drugalcdep.2004.03.010

Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry. 2014;53(2):174–87. DOI: https://doi.org/10.1016/j.jaac.2013.11.005

Weiss M, Tannock R, Kratochvil C, Dunn D, Velez-Borras J, Thomason C, et al. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2005;44(7):647–55. DOI: https://doi.org/10.1097/01.chi.0000163280.47221.c9

Perwien AR, Kratochvil CJ, Faries DE, Vaughan BS, Spencer T, Brown RT. Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: what are the long-term health-related quality-of-life outcomes? J Child Adolesc Psychopharmacol. 2006;16(6):713–24. DOI: https://doi.org/10.1089/cap.2006.16.713

Donnelly C, Bangs M, Trzepacz P, Jin L, Zhang S, Witte MM, et al. Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry. 2009;48(2):176–85. DOI: https://doi.org/10.1097/CHI.0b013e318193060e

Brown TE, Holdnack J, Saylor K, Adler L, Spencer T, Williams DW, et al. Effect of atomoxetine on executive function impairments in adults with ADHD. J Atten Disord. 2011;15(2):130–8. DOI: https://doi.org/10.1177/1087054709356165

Adler LA, Spencer TJ, Williams DW, Moore RJ, Michelson D. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord. 2008;12(3):248–53. DOI: https://doi.org/10.1177/1087054708316250

Geller D, Donnelly C, Lopez F, Rubin R, Newcorn J, Sutton V, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(9):1119–27. DOI: https://doi.org/10.1097/chi.0b013e3180ca8385

Bakken RJ, Paczkowski M, Kramer HP, Axelson AA, Williams DW, Malcolm SK, et al. Effects of atomoxetine on attention-deficit/hyperactivity disorder in clinical pediatric treatment settings: a naturalistic study. Curr Med Res Opin. 2008;24(2):449–60. DOI: https://doi.org/10.1185/030079908X253627

Gibson AP. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Ann Pharmacother. 2006;40(6):1134–42. DOI: https://doi.org/10.1345/aph.1G582

Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, et al. Long-acting medications for the treatment of hyperkinetic disorders - a systematic review and European treatment guidelines. Part 2: a quantitative evaluation of long-acting medications. Z Kinder Jugendpsychiatr Psychother. 2008;36(2):97–10. DOI: https://doi.org/10.1024/1422-4917.36.2.97

Yang L, Cao Q, Shuai L, Li H, Chan RCK, Wang Y. Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial. Int J Neuropsychopharmacol. 2012;15(1):15–26. DOI: https://doi.org/10.1017/S1461145711001490

Chamberlain SR, Müller U, Blackwell AD, Clark L, Robbins TW, Sahakian BJ. Neurochemical modulation of response inhibition and probabilistic learning in humans. Science. 2006;311(5762):861–3. DOI: https://doi.org/10.1126/science.1121218

Chamberlain SR, Hampshire A, Müller U, Rubia K, Del Campo N, Craig K, et al. Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study. Biol Psychiatry. 2009;65(7):550–5. DOI: https://doi.org/10.1016/j.biopsych.2008.10.014

de Jong CGW, Van De Voorde S, Roeyers H, Raymaekers R, Allen AJ, Knijff S, et al. Differential effects of atomoxetine on executive functioning and lexical decision in attentiondeficit/hyperactivity disorder and reading disorder. J Child Adolesc Psychopharmacol. 2009;19(6):699–707. DOI: https://doi.org/10.1089/cap.2009.0029

Sumner CR, Gathercole S, Greenbaum M, Rubin R, Williams D, Hollandbeck M, et al. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children with ADHD and dyslexia. Child Adolesc Psychiatry Ment Health. 2009;3:40 DOI: https://doi.org/10.1186/1753-2000-3-40

Wilens TE, Hammerness P, Utzinger L, Schillinger M, Georgiopoulous A, Doyle RL, et al. An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness. J Child Adolesc Psychopharmacol. 2009;19(5):485–92. DOI: https://doi.org/10.1089/cap.2008.0125

Faraone SV, Biederman J, Spencer T, Michelson D, Adler L, Reimherr F, et al. Atomoxetine and stroop task performance in adult attentiondeficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2005;15(4):664–70. DOI: https://doi.org/10.1089/cap.2005.15.664

Gau SS, Shang C. Improvement of executive functions in boys with attention deficit hyperactivity disorder : an open-label follow-up study with once-daily atomoxetine. 2010;243–56. DOI: https://doi.org/10.1017/S1461145709990836

Barton J, Mooney P, Prasad S. Atomoxetine hydrochloride and executive function in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2005;15(2):147–9. DOI: https://doi.org/10.1089/cap.2005.15.147

Yildiz O, Sismanlar SG, Memik NC, Karakaya I, Agaoglu B. Atomoxetine and methylphenidate treatment in children with ADHD: The efficacy, tolerability and effects on executive functions. Child Psychiatry Hum Dev. 2010;42(3):257–69. DOI: https://doi.org/10.1007/s10578-010-0212-3

Cubillo A, Smith AB, Barrett N, Giampietro V, Brammer MJ, Simmons A, et al. Shared and drug-specific effects of atomoxetine and methylphenidate on inhibitory brain dysfunction in medication-naive ADHD boys. Cereb Cortex. 2014;24(1):174–85. DOI: https://doi.org/10.1093/cercor/bhs296

Marquand AF, De Simoni S, O’Daly OG, Williams SCR, Mourão-Miranda J, Mehta MA. Pattern classification of working memory networks reveals differential effects of methylphenidate, atomoxetine, and placebo in healthy volunteers. Neuropsychopharmacology. 2011;36(6):1237–47. DOI: https://doi.org/10.1038/npp.2011.9

Artículos más leídos del mismo autor/a

1 2 > >>